Akiram Therapeutics Advances Clinical Development of Cancer Drug Candidate AKIR001

Swedish biotech company Akiram Therapeutics, specializing in molecular radiotherapy, has announced new preclinical data for its lead candidate, AKIR001. The findings, published in The Journal of Nuclear Medicine, demonstrate selective tumor uptake, clear antitumor effects, and favorable tolerability in preclinical pancreatic cancer models.

These results strengthen the scientific foundation for AKIR001 and align with the company's ongoing clinical development. Akiram has also advanced its ongoing Phase I clinical trial evaluating AKIR001. Cohort 2b has been completed following a safety review, and the study has now advanced to Cohort 3, with results continuing to support a favorable safety profile.

The Phase I trial, conducted at Karolinska University Hospital, has indicated a positive safety profile and encouraging tumor targeting. Previous company announcements show the first patient was enrolled in April 2025, with the first cohort completed in August 2025. The trial aims to assess the safety and tolerability of AKIR001 in patients.

AKIR001 is a targeted radiotherapeutic designed to bind to the CD44v6 marker, which is expressed on certain cancer cells. The development of this therapy represents a step toward new targeted cancer treatments, particularly for challenging-to-treat cancers.